On August 5, 2025 Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, reported the successful completion of equity financing led by Ally Bridge Group (Press release, Mission Bio, AUG 5, 2025, View Source [SID1234654819]). The investment will fund new innovations, commercial partnerships, and clinical adoption. The company’s vision is to accelerate clinical adoption of the company’s Tapestri Platform across multiple cancer segments by providing crucial insights into treatment decision-making. This effort will be supported by the broadening of the platform’s single-cell tri-omics capabilities, which recently added targeted gene expression analysis to genotype analysis in a single assay.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The funding follows Mission Bio’s strong traction with biopharma customers and continued platform innovation. The Tapestri Platform has long been the leading technology for simultaneously generating DNA and protein data from a single cell, allowing researchers and clinicians a unique window into disease development and therapeutic response. Last month, Mission Bio launched its Single-Cell Targeted Genotype and Gene Expression assay, a custom service supporting KOL protocols to profile DNA and – for the first time in one assay – RNA from over 10,000 single cells, an unprecedented leap forward for single-cell multi-omics. In its next phase, Mission Bio will expand its offerings, enabling a variety of uses for characterizing tri-omics – the simultaneous profiling of DNA, RNA, and protein for single cells – at high resolution.
"This strong support from Ally Bridge Group and other investors validates our leadership position in single-cell multi-omics and enables us to take the next step in our mission of transforming precision medicine," said Brian Kim, CEO. "We are now positioned to expand our commercial footprint while advancing our technology to address critical unmet needs in cancer research and treatment."
The funding will support three key initiatives:
Commercial Expansion and Partnerships: Mission Bio will broaden its customer reach to support growing demand from pharmaceutical companies developing next-generation cancer therapies. Recent partnerships, including a collaboration with Integrated DNA Technologies (IDT), a Danaher company, demonstrate industry confidence in the Tapestri Platform’s ability to deliver comprehensive insights for drug development. Furthermore, Mission Bio will expand its commercial reach through distribution agreements that help access new market opportunities.
Development of Single-Cell Tri-omics Capabilities: The company will advance its platform to include targeted RNA analysis alongside existing DNA and protein capabilities. This enhancement responds to consistent customer demand for integrated genotype and gene expression data, enabling researchers to understand mechanisms of action and resistance in cancer therapies. The tri-omics capability will support applications beyond patient stratification, including patient safety assessments.
Accelerated Clinical Adoption: Mission Bio will expand the clinical utility of Tapestri across multiple cancer segments, including multiple myeloma, myeloid malignancies, and CAR-T cell therapy applications. The platform’s ability to provide comprehensive sample-to-answer solutions empowers clinicians to accelerate personalized treatment guidance. One promising initiative is using Mission Bio’s Tapestri Single-cell Myeloid Multiomics Assay to correlate relapse with complex clonal architecture, surpassing the limitations of existing methods like NGS or FLO and revealing novel biomarkers for therapeutic targets.
Mission Bio is well known for breakthrough innovation in single-cell analytics that has unlocked novel insights for its customers. In addition to its latest tri-omics offering, the Tapestri Platform was recently featured in a publication where its single-cell Myeloid Multi-omics solution was used as a highly sensitive molecular test to confirm long-term remission for patients with IDH1-mutant AML who received olutasidenib, the latest demonstration of how the industry is using Tapestri as a high-resolution MRD assay leading to actionable insights.
"Mission Bio’s single-cell tri-omics platform represents exactly the type of transformative life science innovation we seek to support," said Kevin Reilly, Managing Director at Ally Bridge Group. "This investment reflects our continued conviction that Mission Bio’s technology will become essential infrastructure for precision medicine, particularly as the industry shifts toward more complex cell and gene therapies requiring comprehensive characterization at the individual cell level."
Mission Bio has also expanded its leadership team with the addition of Matthew H. Cato as the company’s new Chief Commercial Officer. Cato has held senior marketing and business development positions with the company since 2017, and will help expand the company’s commercial leadership in the multi-omics space.